For Q1 FY2026 ended April 3, 2026, STAAR Surgical reported revenue of $93.5 million, up 119.6% year-over-year. Net income was $5.2 million, compared to a loss in the prior year, with diluted EPS of $0.10. Operating income was $8.0 million, and the company held $131.9 million in cash with $352.4 million in equity.
•Revenue surged 119.6% YoY to $93.5 million.
•Net income turned positive at $5.2 million, with diluted EPS of $0.10.
•Operating income reached $8.0 million, a 113.9% increase.
•Cash and equivalents stood at $131.9 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
The company serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives globally. Incorporated in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company's primary product family is the implantable collamer lens (ICL), which includes EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL. These lenses are used in refractive surgery to treat visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company serves healthcare providers including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.
On which stock exchange is STAAR Surgical Company (STAA) listed and what is its trading currency?
STAAR Surgical Company is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol STAA. The trading currency for its shares is the US Dollar (USD), as the company is based in the United States and its stock is traded on a US exchange.
What sector and industry does STAAR Surgical Company (STAA) belong to?
STAAR Surgical Company operates in the Healthcare sector and is classified under the Medical Instruments & Supplies industry. This means the company is involved in the development and manufacturing of medical devices, specifically surgical instruments and supplies used in ophthalmic procedures. Its focus on implantable lenses for vision correction places it within the broader medical device market.
Where is STAAR Surgical Company (STAA) headquartered and what markets does it serve?
STAAR Surgical Company is headquartered in Lake Forest, California, United States. The company was incorporated in 1982. It sells its products globally through its sales representatives, serving healthcare providers such as ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. Its products are used worldwide for refractive surgery to correct vision disorders.
How does STAAR Surgical Company (STAA) generate revenue?
STAAR Surgical Company generates revenue by selling its implantable collamer lenses (ICLs) and accessory delivery systems to healthcare providers. The company's product family includes EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL, which are used in refractive surgery to treat myopia, hyperopia, astigmatism, and presbyopia. STAAR sells its products directly through its sales representatives globally, serving ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company's revenue is primarily driven by the volume of ICL procedures performed and the adoption of its lenses as an alternative to laser vision correction.